{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:53:18Z","timestamp":1789811598836,"version":"4.0.1"},"reference-count":74,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide, with its advanced stages presenting significant challenges for the clinical oncologist. Axl is a member of the TAM family of receptor tyrosine kinases that is becoming increasingly important in the pathophysiology of (advanced) GC. This receptor, activated by its ligand Gas6 (growth arrest-specific gene 6), is implicated in various oncogenic processes, including cell survival, proliferation, migration, and immune evasion. Overexpression or aberrant activation of Axl has been associated with poor prognosis, tumor aggressiveness, and resistance to conventional therapies in gastric cancer. Objectives: This review aims to consolidate current knowledge on Axl\u2019s role in gastric cancer pathophysiology and explore its therapeutic implications. Materials and Methods: A thorough search was conducted in the most relevant online databases, using different combinations of the following terms: Axl, GC, pathophysiology, and therapeutic target. Results: In the first part, the molecular mechanisms of Axl in tumors, which involve, among others, the activation of downstream signaling pathways, including PI3K\/AKT, MAPK\/ERK, and NF-\u03baB, are discussed. Subsequently, potential treatments targeting Axl and potential combination therapies are highlighted, based on the encouraging results from preclinical and clinical studies. Finally, as the Axl\u2013tumor microenvironment interplay is discussed, with therapeutic implications, it thus opens new pathways for research on effective treatments in advanced gastric cancer. Conclusions: Understanding Axl\u2019s role in the pathophysiology of GC is essential to develop efficient targeted therapies with improved clinical effects.<\/jats:p>","DOI":"10.3390\/medicina61091619","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T08:06:32Z","timestamp":1757318792000},"page":"1619","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Receptor Tyrosine Kinase Axl in (Advanced) Gastric Cancer\u2014From Pathophysiology to Therapeutic Impact"],"prefix":"10.3390","volume":"61","author":[{"given":"Oliver Daniel","family":"Schreiner","sequence":"first","affiliation":[{"name":"Department of Medical Specialties III, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Medical Oncology Department, Regional Institute of Oncology, 700483 Iasi, Romania"},{"name":"Department of Electrical Measurements and Materials, Gheorghe Asachi Technical University, 700050 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Gabriel","family":"Schreiner","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties III, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"First Neurology Clinic, \u201cN. Oblu\u201d Clinical Emergency Hospital, 700309 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-8893","authenticated-orcid":false,"given":"Lucian","family":"Miron","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties III, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Medical Oncology Department, Regional Institute of Oncology, 700483 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romeo Cristian","family":"Ciobanu","sequence":"additional","affiliation":[{"name":"Department of Electrical Measurements and Materials, Gheorghe Asachi Technical University, 700050 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Machlowska, J., Baj, J., Sitarz, M., Maciejewski, R., and Sitarz, R. (2020). Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21114012"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","article-title":"Updates on global epidemiology, risk and prognostic factors of gastric cancer","volume":"29","author":"Yang","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_3","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Wonglhow, J., Tantipisit, J., Wetwittayakhlang, P., Sunpaweravong, P., Sathitruangsak, C., Kanjanapradit, K., Thongwatchara, P., and Dechaphunkul, A. (2025). Association Between Epstein-Barr Virus Infection and PD-L1 Expression in Gastric Cancer: Prevalence, Clinicopathological Features, and Prognostic Implications. Cancers, 17.","DOI":"10.3390\/cancers17091492"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104482","DOI":"10.1016\/j.esmoop.2025.104482","article-title":"Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project","volume":"10","author":"Dienstmann","year":"2025","journal-title":"ESMO Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/SLA.0000000000004303","article-title":"Comprehensive Molecular Characterization of Adenocarcinoma of the Gastroesophageal Junction Between Esophageal and Gastric Adenocarcinomas","volume":"275","author":"Suh","year":"2022","journal-title":"Ann. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-21-3435","article-title":"Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)","volume":"28","author":"Hua","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1002\/mco2.446","article-title":"Receptor tyrosine kinases: Biological functions and anticancer targeted therapy","volume":"4","author":"Zhang","year":"2023","journal-title":"MedComm"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Yamaguchi, H., Nagamura, Y., and Miyazaki, M. (2022). Receptor Tyrosine Kinases Amplified in Diffuse-Type Gastric Carcinoma: Potential Targeted Therapies and Novel Downstream Effectors. Cancers, 14.","DOI":"10.3390\/cancers14153750"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/bjc.2014.61","article-title":"HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma","volume":"110","author":"Liu","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wium, M., Ajayi-Smith, A.F., Paccez, J.D., and Zerbini, L.F. (2021). The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications. Cancers, 13.","DOI":"10.3390\/cancers13071521"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Engelsen, A.S.T., Lotsberg, M.L., Khouzam, R.A., Thiery, J.-P., Lorens, J.B., Chouaib, S., and Terry, S. (2022). Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.869676"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","article-title":"AXL signaling in cancer: From molecular insights to targeted therapies","volume":"10","author":"Yadav","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Repici, A., Ardizzone, A., De Luca, F., Colarossi, L., Prestifilippo, A., Pizzino, G., Paterniti, I., Esposito, E., and Capra, A.P. (2024). Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma. Cells, 13.","DOI":"10.3390\/cells13040361"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","article-title":"AXL in cancer: A modulator of drug resistance and therapeutic target","volume":"42","author":"Tang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: Functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.emboj.7600912","article-title":"Structural basis for Gas6-Axl signalling","volume":"25","author":"Sasaki","year":"2006","journal-title":"EMBO J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zhai, X., Pu, D., Wang, R., Zhang, J., Lin, Y., Wang, Y., Zhai, N., Peng, X., Zhou, Q., and Li, L. (2023). Gas6\/AXL pathway: Immunological landscape and therapeutic potential. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1121130"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7486","DOI":"10.3390\/cimb46070444","article-title":"Could Gas6\/TAM Axis Provide Valuable Insights into the Pathogenesis of Systemic Sclerosis?","volume":"46","author":"Apostolo","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.tibs.2017.06.004","article-title":"Phosphatidylserine Is the Signal for TAM Receptors and Their Ligands","volume":"42","author":"Lemke","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Bosch, N., Crist\u00f3bal, H., Iglesias, M., Gironella, M., Barranco, L., Visa, L., Calafato, D., Jim\u00e9nez-Parrado, S., Earl, J., and Carrato, A. (2022). Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. EBioMedicine, 75.","DOI":"10.1016\/j.ebiom.2021.103797"},{"key":"ref_22","first-page":"e1912","article-title":"MAPK\/ERK and PI3K\/AKT signaling pathways are activated in adolescent and adult acute lymphoblastic leukemia","volume":"6","author":"Loureiro","year":"2023","journal-title":"Cancer Rep."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kim, C.-W., Lee, J.M., and Park, S.W. (2024). Divergent roles of the regulatory subunits of class IA PI3K. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1152579"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-15-1458","article-title":"Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy","volume":"22","author":"Scaltriti","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-024-02210-9","article-title":"AXL: Shapers of tumor progression and immunosuppressive microenvironments","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4062\/biomolther.2020.051","article-title":"Synergistic Induction of Apoptosis by the Combination of an Axl Inhibitor and Auranofin in Human Breast Cancer Cells","volume":"28","author":"Ryu","year":"2020","journal-title":"Biomol Ther"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"113067","DOI":"10.1016\/j.celrep.2023.113067","article-title":"AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages","volume":"42","author":"Hung","year":"2023","journal-title":"Cell Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/onc.2013.57","article-title":"AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells","volume":"33","author":"Asiedu","year":"2014","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.3892\/ol.2016.5369","article-title":"Biomarkers for EMT and MET in breast cancer: An update","volume":"12","author":"Liu","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40164-023-00446-7","article-title":"Focal adhesion kinase: From biological functions to therapeutic strategies","volume":"12","author":"Tan","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.18632\/oncotarget.26882","article-title":"Axl signaling is an important mediator of tumor angiogenesis","volume":"10","author":"Tanaka","year":"2019","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sperb, N., Tsesmelis, M., and Wirth, T. (2020). Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155486"},{"key":"ref_33","first-page":"843","article-title":"In vitro and in vivo antiangiogenic activity of desacetylvinblastine monohydrazide through inhibition of VEGFR2 and Axl pathways","volume":"6","author":"Lei","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_34","first-page":"152","article-title":"Adaptive resistance to targeted therapies in cancer","volume":"2","author":"Rosell","year":"2013","journal-title":"Transl. Lung. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"eabk2746","DOI":"10.1126\/sciadv.abk2746","article-title":"Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer","volume":"8","author":"Arenas","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Pidkovka, N., and Belkhiri, A. (2023). Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: A promising therapeutic target. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1079041"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ho, H., Cheng, C.-Y., Huang, C.-Y., Chu, S.-E., Liang, Y.-J., Sun, J.-T., and Chen, Y.-L. (2024). Association Between Phosphorylated AXL Expression and Survival in Patients with Gastric Cancer. J. Clin. Med., 13.","DOI":"10.3390\/jcm13226694"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zhou, J., Kong, Q., Liu, X., and Huang, Y. (2025). Integrated analysis of myeloperoxidase in gastric health and cancer: Associations with pepsinogen levels, immune regulation, and prognosis in a large healthy population-based and TCGA cohorts. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1590257"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/OTT.S150952","article-title":"The prognostic role of Gas6\/Axl axis in solid malignancies: A meta-analysis and literature review","volume":"11","author":"Zhang","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_40","first-page":"48","article-title":"Accuracy of serum Axl as a biomarker for early and advanced hepatocellular carcinoma","volume":"62","author":"Reichl","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Flem-Karlsen, K., McFadden, E., Ann Fl\u00f8renes, V., and Davidson, B. (2020). Soluble AXL is a marker of disease progression and prognosis in malignant melanoma. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0227187"},{"key":"ref_42","first-page":"885","article-title":"Soluble AXL as a novel diagnostic biomarker for pancreatic cancer: Improving the performance of CA 19\u20139","volume":"15","author":"Iglesias","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kimani, S.G., Kumar, S., Bansal, N., Singh, K., Kholodovych, V., Comollo, T., Peng, Y., Kotenko, S.V., Sarafianos, S.G., and Bertino, J.R. (2017). Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity. Sci. Rep., 7.","DOI":"10.1038\/srep43908"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/0008-5472.CAN-09-2997","article-title":"R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer","volume":"70","author":"Holland","year":"2010","journal-title":"Cancer Res."},{"key":"ref_45","first-page":"1466","article-title":"Axl inhibitor R428 induces apoptosis of cancer cells by blocking lysosomal acidification and recycling independent of Axl inhibition","volume":"8","author":"Chen","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Yang, R., Li, Y., Wang, H., Qin, T., Yin, X., and Ma, X. (2022). Therapeutic progress and challenges for triple negative breast cancer: Targeted therapy and immunotherapy. Mol. Biomed., 3.","DOI":"10.1186\/s43556-022-00071-6"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1038\/s41375-023-02029-1","article-title":"Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial","volume":"37","author":"Kubasch","year":"2023","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/1535-7163.MCT-21-0293","article-title":"AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1158\/2326-6066.CIR-22-0254","article-title":"AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells","volume":"11","author":"Sakemura","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.18632\/oncotarget.2542","article-title":"AXL kinase as a novel target for cancer therapy","volume":"5","author":"Wu","year":"2014","journal-title":"Oncotarget"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1158\/1078-0432.CCR-16-1316","article-title":"Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis","volume":"23","author":"Leconet","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_52","first-page":"145","article-title":"Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugate","volume":"8","author":"Chang","year":"2025","journal-title":"Antib. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nm.4472","article-title":"Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF\/MEK inhibitors","volume":"24","author":"Boshuizen","year":"2018","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Tanaka, M., and Siemann, D.W. (2021). Therapeutic Targeting of the Gas6\/Axl Signaling Pathway in Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22189953"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1172\/JCI85610","article-title":"Inhibition of the GAS6\/AXL pathway augments the efficacy of chemotherapies","volume":"127","author":"Kariolis","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2021.08.020","article-title":"Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer","volume":"163","author":"Fuh","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s10120-020-01066-4","article-title":"Inhibiting the GAS6\/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma","volume":"23","author":"Bae","year":"2020","journal-title":"Gastric Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/mco2.11","article-title":"A dual MET\/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment","volume":"1","author":"Zhu","year":"2020","journal-title":"MedComm"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/1878-0261.13654","article-title":"Proteome-based molecular subtyping and therapeutic target prediction in gastric cancer","volume":"18","author":"Hu","year":"2024","journal-title":"Mol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ma, Y.-X., Liu, F.-R., Zhang, Y., Chen, Q., Chen, Z.-Q., Liu, Q.-W., Huang, Y., Yang, Y.-P., Fang, W.-F., and Xi, N. (2022). Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1024755"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Son, H.Y., and Jeong, H.K. (2021). Immune Evasion Mechanism and AXL. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.756225"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Yeo, X.H., Sundararajan, V., Wu, Z., Phua, Z.J.C., Ho, Y.Y., Peh, K.L.E., Chiu, Y.C., Tan, T.Z., Kappei, D., and Ho, Y.S. (2023). The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer. Commun Biol., 6, Erratum in Commun Biol. 2023, 6, 759. https:\/\/doi.org\/10.1038\/s42003-023-05139-9.","DOI":"10.1038\/s42003-023-05139-9"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40164-024-00566-8","article-title":"AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: From current progress to novel strategies","volume":"13","author":"Vandewalle","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1158\/0008-5472.CAN-17-2433","article-title":"Activation of the Receptor Tyrosine Kinase AXL regulates the Immune Microenvironment in Glioblastoma","volume":"78","author":"Sadahiro","year":"2018","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Lee, W., Kim, D.K., Synn, C.-B., Lee, H.K., Park, S., Jung, D.-S., Choi, Y., Kim, J.H., Byeon, Y., and Kim, Y.S. (2022). Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.821391"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Rayford, A., G\u00e4rtner, F., Ramnefjell, M.P., Lorens, J.B., Micklem, D.R., Aanerud, M., and Engelsen, A.S.T. (2024). AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1444007"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Marino, F.Z., Della Corte, C.M., Ciaramella, V., Erra, S., Ronchi, A., Fiorelli, A., Vicidomini, G., Santini, M., Scognamiglio, G., and Morgillo, F. (2022). AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma. J. Pers. Med., 12.","DOI":"10.3390\/jpm12121993"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"15397","DOI":"10.1074\/jbc.RA118.003063","article-title":"HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion","volume":"293","author":"Li","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"ra66","DOI":"10.1126\/scisignal.2004155","article-title":"The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells","volume":"6","author":"Meyer","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Auyez, A., Sayan, A.E., Kriajevska, M., and Tulchinsky, E. (2021). AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew. Cancers, 13.","DOI":"10.3390\/cancers13194864"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"103270","DOI":"10.1016\/j.isci.2021.103270","article-title":"AXL cooperates with EGFR to mediate neutrophil elastase-induced migration of prostate cancer cells","volume":"24","author":"Xiao","year":"2021","journal-title":"iScience"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Kanzaki, R., Naito, H., Kise, K., Takara, K., Eino, D., Minami, M., Shintani, Y., Funaki, S., Kawamura, T., and Kimura, T. (2017). Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-10873-2"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"976","DOI":"10.21037\/tcr.2019.06.06","article-title":"A retrospective analysis of the correlation between AXL expression and clinical outcomes of patients with urothelial bladder carcinoma","volume":"8","author":"Wang","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"100204","DOI":"10.1016\/j.crphar.2024.100204","article-title":"Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies","volume":"7","author":"Iweala","year":"2024","journal-title":"Curr. Res. Pharmacol. Drug Discov."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1619\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:41:44Z","timestamp":1760035304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":74,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medicina61091619"],"URL":"https:\/\/doi.org\/10.3390\/medicina61091619","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}